Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; and.
Department of Diagnostic Imaging, Nuclear Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
J Nucl Med. 2023 Dec 1;64(12):1895-1898. doi: 10.2967/jnumed.123.266185.
Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine tumors (NETs) has not been well characterized using PET imaging. Understanding the degree and uniformity of SSTR expression is important to establish the role of SSTR-targeted treatments in lung NETs. A retrospective institutional review of patients with metastatic lung NETs who underwent DOTATATE PET imaging from March 2017 to February 2023 was performed. In total, 48 patients with metastatic lung NETs who underwent Ga- or Cu-DOTATATE PET imaging were identified. Four had completely negative SSTR expression, and 10 had very weak expression (less than in a normal liver). Among the remaining 34 patients, 21 had uniformly positive DOTATATE PET scans, and 13 had heterogeneous expression. Only 44% had uniformly positive receptor expression, identifying them as candidates for peptide receptor radionuclide therapy. Most metastatic lung NETs lack uniform SSTR expression and are thus suboptimal candidates for SSTR-targeted therapy. SSTR imaging in lung NETs should be evaluated carefully for uniformity of expression.
使用 PET 成像对转移性肺神经内分泌肿瘤 (NET) 中的生长抑素受体 (SSTR) 表达进行了很好的描述。了解 SSTR 表达的程度和均匀性对于确定 SSTR 靶向治疗在肺 NET 中的作用非常重要。
回顾性分析了 2017 年 3 月至 2023 年 2 月间接受 DOTATATE PET 成像的转移性肺 NET 患者的机构审查。共发现 48 例接受 Ga 或 Cu-DOTATATE PET 成像的转移性肺 NET 患者。其中 4 例完全无 SSTR 表达，10 例表达非常弱（低于正常肝脏）。在其余 34 例患者中，21 例 DOTATATE PET 扫描结果阳性，13 例表现为异质性表达。仅有 44% 的患者具有均匀的阳性受体表达，将其确定为肽受体放射性核素治疗的候选者。
大多数转移性肺 NET 缺乏均匀的 SSTR 表达，因此不是 SSTR 靶向治疗的理想候选者。在肺 NET 中，SSTR 成像应仔细评估其表达的均匀性。
